APO RESEARCH · REPORT
Latisse (Bimatoprost)
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Product & engineering
Understand the product.
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Selected research
Industry Research
Latisse (Bimatoprost) Industry Research Report 2026
Market perspective
Bimatoprost (CAS 155206-00-1), also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.
Global Latisse (Bimatoprost) (CAS 155206-00-1) key players include Chirogate International, Cayman Pharma, Zhejiang Ausun, Everlight Chemical, and Lianmin Biochemical etc. Global top three players hold a share about 40%. North America is the largest market, with a share about 90%.
Report Scope
Read the full market overview
This report quantifies the global Latisse (Bimatoprost) market in terms of revenue (US$ million) and, where applicable, sales volume (g), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/g) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Latisse (Bimatoprost) Market by Company
Cayman Pharma
Tecoland Corporation
TCS Group
Changzhou BOHIV
Zhejiang Ausun
Ansion Pharma
Lianmin Biochemical
Chirogate International
Everlight Chemical
GENTEC
Latisse (Bimatoprost) Segment by Purity
Below 99.5%
Other
Latisse (Bimatoprost) Segment by Application
Patented Product
General Products
Latisse (Bimatoprost) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Latisse (Bimatoprost) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Latisse (Bimatoprost) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Latisse (Bimatoprost).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Latisse (Bimatoprost) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Latisse (Bimatoprost) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Latisse (Bimatoprost) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by purity, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Below 99.5%
- Other
Applications
- Patented Product
- General Products
Companies covered
- Cayman Pharma
- Tecoland Corporation
- TCS Group
- Changzhou BOHIV
- Zhejiang Ausun
- Ansion Pharma
- Lianmin Biochemical
- Chirogate International
- Everlight Chemical
- GENTEC
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Latisse (Bimatoprost) Market Size (2021-2032)
- 2.2.2 Global Latisse (Bimatoprost) Sales (2021-2032)
- 2.2.3 Global Latisse (Bimatoprost) Market Average Price (2021-2032)
- 2.3 Latisse (Bimatoprost) by Purity
- 2.3.1 Market Value Comparison by Purity (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Below 99.5%
- 2.3.3 Other
- 2.4 Latisse (Bimatoprost) by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Patented Product
- 2.4.3 General Products
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Latisse (Bimatoprost) Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Latisse (Bimatoprost) Sales (g) of Manufacturers (2021-2026)
- 3.3 Global Latisse (Bimatoprost) Revenue of Manufacturers (2021-2026)
- 3.4 Global Latisse (Bimatoprost) Average Price by Manufacturers (2021-2026)
- 3.5 Global Latisse (Bimatoprost) Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Latisse (Bimatoprost), Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Latisse (Bimatoprost), Product Type & Application
- 3.8 Global Manufacturers of Latisse (Bimatoprost), Established Date
- 3.9 Global Latisse (Bimatoprost) Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Cayman Pharma
- 4.1.1 Cayman Pharma Company Information
- 4.1.2 Cayman Pharma Business Overview
- 4.1.3 Cayman Pharma Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Cayman Pharma Latisse (Bimatoprost) Product Portfolio
- 4.1.5 Cayman Pharma Recent Developments
- 4.2 Tecoland Corporation
- 4.2.1 Tecoland Corporation Company Information
- 4.2.2 Tecoland Corporation Business Overview
- 4.2.3 Tecoland Corporation Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Tecoland Corporation Latisse (Bimatoprost) Product Portfolio
- 4.2.5 Tecoland Corporation Recent Developments
- 4.3 TCS Group
- 4.3.1 TCS Group Company Information
- 4.3.2 TCS Group Business Overview
- 4.3.3 TCS Group Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 TCS Group Latisse (Bimatoprost) Product Portfolio
- 4.3.5 TCS Group Recent Developments
- 4.4 Changzhou BOHIV
- 4.4.1 Changzhou BOHIV Company Information
- 4.4.2 Changzhou BOHIV Business Overview
- 4.4.3 Changzhou BOHIV Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Changzhou BOHIV Latisse (Bimatoprost) Product Portfolio
- 4.4.5 Changzhou BOHIV Recent Developments
- 4.5 Zhejiang Ausun
- 4.5.1 Zhejiang Ausun Company Information
- 4.5.2 Zhejiang Ausun Business Overview
- 4.5.3 Zhejiang Ausun Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Zhejiang Ausun Latisse (Bimatoprost) Product Portfolio
- 4.5.5 Zhejiang Ausun Recent Developments
- 4.6 Ansion Pharma
- 4.6.1 Ansion Pharma Company Information
- 4.6.2 Ansion Pharma Business Overview
- 4.6.3 Ansion Pharma Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ansion Pharma Latisse (Bimatoprost) Product Portfolio
- 4.6.5 Ansion Pharma Recent Developments
- 4.7 Lianmin Biochemical
- 4.7.1 Lianmin Biochemical Company Information
- 4.7.2 Lianmin Biochemical Business Overview
- 4.7.3 Lianmin Biochemical Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Lianmin Biochemical Latisse (Bimatoprost) Product Portfolio
- 4.7.5 Lianmin Biochemical Recent Developments
- 4.8 Chirogate International
- 4.8.1 Chirogate International Company Information
- 4.8.2 Chirogate International Business Overview
- 4.8.3 Chirogate International Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Chirogate International Latisse (Bimatoprost) Product Portfolio
- 4.8.5 Chirogate International Recent Developments
- 4.9 Everlight Chemical
- 4.9.1 Everlight Chemical Company Information
- 4.9.2 Everlight Chemical Business Overview
- 4.9.3 Everlight Chemical Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Everlight Chemical Latisse (Bimatoprost) Product Portfolio
- 4.9.5 Everlight Chemical Recent Developments
- 4.10 GENTEC
- 4.10.1 GENTEC Company Information
- 4.10.2 GENTEC Business Overview
- 4.10.3 GENTEC Latisse (Bimatoprost) Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 GENTEC Latisse (Bimatoprost) Product Portfolio
- 4.10.5 GENTEC Recent Developments
5 Global Latisse (Bimatoprost) Market Scenario by Region
- 5.1 Global Latisse (Bimatoprost) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Latisse (Bimatoprost) Sales by Region: 2021-2032
- 5.2.1 Global Latisse (Bimatoprost) Sales by Region: 2021-2026
- 5.2.2 Global Latisse (Bimatoprost) Sales by Region: 2027-2032
- 5.3 Global Latisse (Bimatoprost) Revenue by Region: 2021-2032
- 5.3.1 Global Latisse (Bimatoprost) Revenue by Region: 2021-2026
- 5.3.2 Global Latisse (Bimatoprost) Revenue by Region: 2027-2032
- 5.4 North America Latisse (Bimatoprost) Market Facts & Figures by Country
- 5.4.1 North America Latisse (Bimatoprost) Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Latisse (Bimatoprost) Sales by Country (2021-2032)
- 5.4.3 North America Latisse (Bimatoprost) Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Latisse (Bimatoprost) Market Facts & Figures by Country
- 5.5.1 Europe Latisse (Bimatoprost) Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Latisse (Bimatoprost) Sales by Country (2021-2032)
- 5.5.3 Europe Latisse (Bimatoprost) Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Latisse (Bimatoprost) Market Facts & Figures by Country
- 5.6.1 Asia Pacific Latisse (Bimatoprost) Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Latisse (Bimatoprost) Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Latisse (Bimatoprost) Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Latisse (Bimatoprost) Market Facts & Figures by Country
- 5.7.1 South America Latisse (Bimatoprost) Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Latisse (Bimatoprost) Sales by Country (2021-2032)
- 5.7.3 South America Latisse (Bimatoprost) Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Latisse (Bimatoprost) Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Latisse (Bimatoprost) Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Latisse (Bimatoprost) Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Latisse (Bimatoprost) Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Purity
- 6.1 Global Latisse (Bimatoprost) Sales by Purity (2021-2032)
- 6.1.1 Global Latisse (Bimatoprost) Sales by Purity (2021-2032) & (g)
- 6.1.2 Global Latisse (Bimatoprost) Sales Market Share by Purity (2021-2032)
- 6.2 Global Latisse (Bimatoprost) Revenue by Purity (2021-2032)
- 6.2.1 Global Latisse (Bimatoprost) Sales by Purity (2021-2032) & (US$ Million)
- 6.2.2 Global Latisse (Bimatoprost) Revenue Market Share by Purity (2021-2032)
- 6.3 Global Latisse (Bimatoprost) Price by Purity (2021-2032)
7 Segment by Application
- 7.1 Global Latisse (Bimatoprost) Sales by Application (2021-2032)
- 7.1.1 Global Latisse (Bimatoprost) Sales by Application (2021-2032) & (g)
- 7.1.2 Global Latisse (Bimatoprost) Sales Market Share by Application (2021-2032)
- 7.2 Global Latisse (Bimatoprost) Revenue by Application (2021-2032)
- 7.2.1 Global Latisse (Bimatoprost) Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Latisse (Bimatoprost) Revenue Market Share by Application (2021-2032)
- 7.3 Global Latisse (Bimatoprost) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Latisse (Bimatoprost) Value Chain Analysis
- 8.1.1 Latisse (Bimatoprost) Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Latisse (Bimatoprost) Production Mode & Process
- 8.2 Latisse (Bimatoprost) Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Latisse (Bimatoprost) Distributors
- 8.2.3 Latisse (Bimatoprost) Customers
9 Global Latisse (Bimatoprost) Analyzing Market Dynamics
- 9.1 Latisse (Bimatoprost) Industry Trends
- 9.2 Latisse (Bimatoprost) Industry Drivers
- 9.3 Latisse (Bimatoprost) Industry Opportunities and Challenges
- 9.4 Latisse (Bimatoprost) Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst